Adjuvant chemotherapy for T1 node-positive colon cancers provides significant survival benefit

Diseases of the Colon and Rectum

Volumn 57, Issue 12, 2014, Pages 1341-1348

  Ganapathi, Asvin M ^a   Speicher, Paul J ^a   Englum, Brian R ^a   Castleberry, Anthony W ^a   Migaly, John ^a   Hsu, David S ^b   Mantyh, Christopher R ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Abdominal malignancy; Colon cancer; Outcomes research

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; COLON CANCER; FEMALE; HUMAN; LONG TERM SURVIVAL; MALE; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; AGE; CANCER STAGING; CLINICAL TRIAL; COLON RESECTION; COLONIC NEOPLASMS; COMPARATIVE STUDY; LENGTH OF STAY; LYMPH NODE METASTASIS; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROGNOSIS; STATISTICS AND NUMERICAL DATA; SURVIVAL; SURVIVOR; TUMOR RECURRENCE; UNITED STATES;

ANTINEOPLASTIC AGENT;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLONIC NEOPLASMS; FEMALE; HUMANS; LENGTH OF STAY; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; UNITED STATES;

EID: 84924712265     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0000000000000245     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Sobin LH, Greene FL. TNM classification: clarification of number of regional lymph nodes for pNo. Cancer. 2001;92:452.
3. Nelson H, Petrelli N, Carlin A, et al; National Cancer Institute Expert Panel. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001;93:583-596.
4. Benson AB 3rd, Arnoletti JP, Bekaii-Saab T, et al; National Comprehensive Cancer Network. Colon cancer. J Natl Compr Canc Netw. 2011;9:1238-1290.
5. Resch A, Langner C. Lymph node staging in colorectal cancer: old controversies and recent advances. World J Gastroenterol. 2013;19:8515-8526.
6. André T, Boni C, Mounedji-Boudiaf L, et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.
7. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352-358.
8. Zaniboni A. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: Impact on disease-free survival and overall survival. J Clin Oncol. 1997;15:2432-2441.
9. Steele SR, Park GE, Johnson EK, et al. The impact of age on colorectal cancer incidence, treatment, and outcomes in an equal-access health care system. Dis Colon Rectum. 2014;57:303-310.
10. Chok KS, Law WL. Prognostic factors affecting survival and recurrence of patients with pT1 and pT2 colorectal cancer. World J Surg. 2007;31:1485-1490.
11. Wang H, Wei XZ, Fu CG, Zhao RH, Cao FA . Patterns of lymph node metastasis are different in colon and rectal carcinomas. World J Gastroenterol. 2010;16:5375-5379.
12. D'Agostino RB, Rubin, DB. Missing data estimating and using propensity scores with partially missing data. J Am Statist Assoc. 2000;95:749-759.
13. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38:1228-1234.
14. NCCN Guidelines Version 3. 2014 Colon Cancer. Available at http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf. Accessed April 4, 2014.
15. Okabe S, Shia J, Nash G, et al. Lymph node metastasis in T1 adenocarcinoma of the colon and rectum. J Gastrointest Surg. 2004;8:1032-1040.
16. Wang HS, Liang WY, Lin TC, et al. Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and longterm prognosis. Dis Colon Rectum. 2005;48:1182-1192.
17. Suzuki T, Sadahiro S, Mukoyama S, et al. Risk of lymph node and distant metastases in patients with early invasive colorectal cancer classified as Haggitt's level 4 invasion: Image analysis of submucosal layer invasion. Dis Colon Rectum. 2003;46:203-208.
18. Sakuragi M, Togashi K, Konishi F, et al. Predictive factors for lymph node metastasis in T1 stage colorectal carcinomas. Dis Colon Rectum. 2003;46:1626-1632.
19. Nakadoi K, Oka S, Tanaka S, et al. Condition of muscularis mucosae is a risk factor for lymph node metastasis in T1 colorectal carcinoma. Surg Endosc. 2014;28:1269-1276.
20. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109-3116.
21. Jorgensen ML, Young JM, Dobbins TA, Solomon MJ. Does patient age still affect receipt of adjuvant therapy for colorectal cancer in New South Wales, Australia? J Geriatr Oncol. 2014;5:323-330.
22. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93:850-857.
23. Hamza S, Bouvier AM, Rollot F, Lepage C, Faivre J, Bedenne L. Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: A population-based study. Ann Surg Oncol. 2014;21: 2636-2641.
24. Merkow RP, Bentrem DJ, Mulcahy MF, et al. Effect of postoperative complications on adjuvant chemotherapy use for stage III colon cancer. Ann Surg. 2013;258:847-853.